<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Oncol Rep</journal-id><journal-title-group><journal-title>Current Oncology Reports</journal-title></journal-title-group><issn pub-type="ppub">1523-3790</issn><issn pub-type="epub">1534-6269</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39862354</article-id><article-id pub-id-type="pmc">PMC11861007</article-id>
<article-id pub-id-type="publisher-id">1632</article-id><article-id pub-id-type="doi">10.1007/s11912-024-01632-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ritter</surname><given-names>Alina S.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Poppinga</surname><given-names>Jelte</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Steinkraus</surname><given-names>Kira C.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hackert</surname><given-names>Thilo</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nie&#x000df;en</surname><given-names>Anna</given-names></name><address><email>an.niessen@uke.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zgy1s35</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution>Department of General, Visceral and Thoracic Surgery, </institution><institution>University Medical Center Hamburg- Eppendorf, </institution></institution-wrap>Martinistra&#x000df;e 52, D-20246 Hamburg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>27</volume><issue>2</issue><fpage>157</fpage><lpage>167</lpage><history><date date-type="accepted"><day>24</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose of Review</title><p id="Par1">Neuroendocrine tumours (NET) are rare entities arising from hormone producing cells in the gastroentero-pancreatic (GEP) tract. Surgery is the most common treatment of GEP-NETs.</p></sec><sec><title>Recent Findings</title><p id="Par2">Improvements in surgical techniques allow for more locally advanced and metastasised GEP-NETs to be resected. Laparoscopic and robotically--assisted approaches are increasingly being utilised in the resection of selected GEP-NETs and are facilitated by novel intraoperative tumour localisation tools and parenchyma-sparing methods. At the same time, some authors suggest that indications for formal resections of small well differentiated non-functioning pancreatic NETs and appendiceal NETs should be more restrictive.</p></sec><sec><title>Summary</title><p id="Par3">Advancements in surgery allows for tissue-sparing resections of GEP-NETs. Indications for surgical resection and the extent of the procedure are highly dependent on GEP-NET size, localisation and grading. Robotically assisted surgeries with intraoperative ultrasound and visualisation methods as well as vessel-sparing radical retrograde lymphadenectomies for small intestinal NETs seem to be the future of GEP-NET surgery.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Neuroendocrine tumour</kwd><kwd>Pancreatic neuroendocrine tumour</kwd><kwd>Intestinal neuroendocrine tumour</kwd><kwd>GEP-NET</kwd><kwd>Oncologic surgery</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#x000e4;tsklinikum Hamburg-Eppendorf (UKE) (5411)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Neuroendocrine tumours (NETs) are rare neoplasms, deriving form hormone-producing cells, with a rising incidence [<xref ref-type="bibr" rid="CR1">1</xref>]. The most frequent localisation of NETs is the lung, followed by the gastroentero-pancreatic system. Surgical resection remains the most common treatment for gastroentero-pancreatic NETs (GEP-NET) [<xref ref-type="bibr" rid="CR2">2</xref>]. Current guidelines by the European Neuroendocrine Tumor Society (ENETS) and the North American Neuroendocrine Tumor Society (NANETS) recommend resection depending on tumour localization, tumour size, proliferation index and functional activity [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Apart from surgery, somatostatin analogues (SSAs), peptide receptor radionuclide therapy (PRRT) and chemotherapy are the main pillars in modern GEP-NET treatment [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. In case of non-resectable metastasis local ablative treatments such as microwave ablation (MWA) or radiofrequency ablation (RFA) as well as transarterial approaches like transarterial (chemo-)embolization (TA(C)E) and selective internal radiotherapy (SIRT) can be applied [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par5">Prognosis of localised, well-differentiated GEP-NETs is excellent after R0 resection [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Simultaneously, the survival benefits of a R0 resection need to outweigh the risks and complication rates of surgery [<xref ref-type="bibr" rid="CR11">11</xref>]. Severe complications occur in approximately 14.9% after GEP-NET resections, but are highly dependent on the anatomic region, with pancreatic surgery being associated with the highest complication rates [<xref ref-type="bibr" rid="CR11">11</xref>]. Selection of the appropriate surgical procedure and resection technique based on preoperative imaging and the current literature for the individual patient remains the key challenge in surgery for GEP-NETs.</p><p id="Par6">This review aims to give an overview over the recent advancements in GEP-NET surgery focusing on current indications for resection, the appropriate resection extent and especially novel technological developments in order to improve GEP-NET resections.</p></sec><sec id="Sec2"><title>Pancreatic NETs &#x02013; to Resect or Not to Resect that is the Question</title><sec id="Sec3"><title>Surveillance of Pancreatic NETs&#x02009;&#x02264;&#x02009;2 cm</title><p id="Par7">The incidence of pancreatic NETs (pNETs) is rising and with improvements of imaging modalities, even smaller lesions can nowadays be identified [<xref ref-type="bibr" rid="CR1">1</xref>]. The survival benefit of surgery needs to be weighed against the morbidity and potential mortality that is associated with pancreatic surgery. European and North-American Guidelines have recommended surgical resection of non-functioning pNETs (nf-pNETs) only from a size cutoff&#x02009;&#x02265;&#x02009;2 cm, however, these recommendations are based on retrospective study designs and remain debated [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. To improve the strength of evidence for the optimal treatment of small, nf-pNETs, a Dutch multi-centre (PANDORA) and an international (ASPEN), prospective observational trial have been initiated [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The interim analyses of both studies published thus far, found a watch-and-wait strategy with regular long-term follow-up to be feasible and safe despite a risk of tumour progression with need for surgery between 2% and 11% respectively for pNETs&#x02009;&#x02264;&#x02009;2 cm [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Thus, the final results of these studies need to be awaited before definitive conclusions can be drawn.</p><p id="Par8">Indication for resection of small nf-pNETs may be restricted to high Ki-67 (higher grading), tumour growth, pathological lymph node enlargement, vascular involvement, signs of local infiltration, pancreatic duct dilatation, distant metastasis or patient request. In contrast, a retrospective analysis of the American National Cancer Database found a significantly improved 5-year overall survival in patients, who underwent resection of pNETs between 1 and 2 cm. This benefit was, however, not detectable after resection of even smaller pNETs (&#x0003c;&#x02009;1 cm) [<xref ref-type="bibr" rid="CR16">16</xref>]. Additionally, enucleation of small nf-pNETs&#x02009;&#x0003c;&#x02009;3 cm is a safe and feasible procedure with similar complication rates and comparable long-term results [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par9">Due to these controversial findings, current ENETS guidelines recommend active surveillance for nf-pNETs&#x02009;&#x02264;&#x02009;1 cm and a personalized approach for nf-pNETs between 1 and 2 cm in size, whereas main pancreatic duct dilation and a tumour size&#x02009;&#x0003e;&#x02009;2 cm are generally indications for surgical resection [<xref ref-type="bibr" rid="CR5">5</xref>].</p></sec><sec id="Sec4"><title>Parenchyma Sparing vs. Formal Resection of Pancreatic NETs</title><p id="Par10">Parenchyma-sparing as well as formal oncological resections are both well-established surgical concepts in treating pNETs. The risk of metastases and recurrence has to be balanced with the risk of overtreatment, potential postoperative complications as well as exocrine and endocrine pancreatic insufficiency due to more radical resections. Thus, there is an ongoing debate on the adequate extent of pNET resections and the role of systematic lymphadenectomy also for localised approaches.</p><p id="Par11">In functionally-active pNETs (f-pNETs), indications for the respective approaches are well defined: Insulinomas, the most common type of f-pNET, can safely be resected with parenchyma-sparing procedures such as enucleation without routine lymphadenectomy, since the risk of malignancy is low [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. In contrast, gastrinomas require formal resection with adequate lymphadenectomy, as lymph node metastases are present in 80% of patients, even in very small (&#x0003c;&#x02009;5 mm) gastrinomas and tumours thus have a more malignant behaviour [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par12">The appropriate approach for nf-pNETs is, however, less well-defined. Whilst formal resection with systematic lymphadenectomy presents the gold standard for most malignant entities, the decision for formal resection and/or systematic lymphadenectomy in nf-pNET patients is based on tumour size, grading and the presence of metastases [<xref ref-type="bibr" rid="CR5">5</xref>]. Additional risk factors for recurrence of nf-pNETs include perineural invasion, Chromogranin A levels, molecular factors and symptoms due to local tumour progression (e.g. jaundice, pain or bleeding) [<xref ref-type="bibr" rid="CR5">5</xref>]. In small, well-differentiated nf-pNETs that are distant to the main pancreatic duct, enucleation can safely be performed with shorter operating times, lower rates of postoperative diabetes and non-inferior oncologic outcome [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In some studies enucleation was associated with higher rates of postoperative pancreatic fistulas, however, not resulting in a higher postoperative overall morbidity and mortality [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Simultaneously, the prognostic impact of lymph node metastases in nf-pNETs remains controversial: While some studies report an association between lymph node metastases and overall- and disease-free survival in pNETs, other studies challenge this concept or limit the prognostic impact to certain subgroups only [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par13">Currently, according to ENETS guidelines enucleation for nf-pNETs between 2 and 3 cm may be carefully considered depending on the patient&#x02019;s individual risk constellation [<xref ref-type="bibr" rid="CR5">5</xref>]. Furthers studies are needed to identify which patients with nf-pNET profit from formal resection, lymphadenectomy or lymph node picking only in contrast to low risk patients, when parenchyma-sparing resections are sufficient.</p></sec><sec id="Sec5"><title>Robotic Surgery for Pancreatic NETs</title><p id="Par14">Over the last 20 years, robotic pancreatic surgery has advanced from a novel more or less experimental technique to a standard approach in high-volume pancreatic centres [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. A lot of experience has been gained in the robotic resection of the far more common pancreatic ductal adenocarcinoma (PDAC) and these technical advancements can likewise be applied in pNETs [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In terms of oncological radicality, robotic resections are not inferior to laparoscopic or open approaches for PDAC [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Spleen-preserving procedures can more frequently be achieved in robotic distal pancreatectomies [<xref ref-type="bibr" rid="CR33">33</xref>]. Simultaneously, minimally invasive resection of nf-pNETs is associated with a shorter hospital stay, a reduced complication rate and similar overall survival compared to open pancreatic resection [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par15">A disadvantage of robotic surgery is the lack of haptic feedback making intraoperative tumour localisation by palpation not conductible, thus requiring precise preoperative imaging. Intraoperative ultrasound and tumour visualization tools are promising strategies to compensate for this drawback, if an NET cannot be visualized in preoperative cross-sectional imaging [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Novel approaches to facilitate intraoperative GEP-NETs localisation are outlined in detail below.<fig id="Fig1"><label>Fig. 1</label><caption><p>Intraoperative ultrasound (<bold>A</bold>) and colour-coded duplex sonography (<bold>B</bold>) during robotic resection of a well-differentiated insulinoma (arrows) in the pancreatic tail</p></caption><graphic xlink:href="11912_2024_1632_Fig1_HTML" id="MO1"/></fig></p><p id="Par16">A recent meta-analysis compared minimally invasive with open resection of nf-pNETs and found a significantly shorter hospital stay and lower blood loss associated with minimally invasive surgery (MIS) [<xref ref-type="bibr" rid="CR38">38</xref>]. Complication rates did not significantly differ, however there was a trend towards lower complication rates after MIS distal pancreatectomy [<xref ref-type="bibr" rid="CR38">38</xref>]. Thus, MIS appears a safe and feasible approach for the resection of nf-pNETs. However, data on long-term results and oncologic outcomes, as well as randomised data is lacking.</p><p id="Par17">Pancreatic NETs appear to be suitable indications for robotically-assisted procedures due to their &#x02013; in comparison with PDAC &#x02013; less aggressive growth patterns, however, specific data on robotic resection of pNETs is scarce. In experienced centres, robotic and laparoscopic resection of pNETs may be encouraged in suitable patients [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="Sec6"><title>Portal Vein Resection of Locally Advanced Pancreatic NETs</title><p id="Par18">Pancreatic tumours are non-functional in 50&#x02013;85% of cases, frequently delaying initial diagnosis to an advanced tumour stage [<xref ref-type="bibr" rid="CR5">5</xref>]. Surgical resection remains the treatment of choice for larger nf- and any size of functional-pNET [<xref ref-type="bibr" rid="CR5">5</xref>]. As for PDAC in the pancreatic head local, resectability mostly depends on the degree of vessel involvement. The International Study Group of Pancreatic Surgery (ISGPS) has defined PDACs as resectable, borderline resectable, locally advanced and irresectable based on the involvement of the superior mesenteric vein (SMV) or portal vein (PV) as well as the celiac trunk (CT), hepatic artery (HA) and superior mesenteric artery (SMA) [<xref ref-type="bibr" rid="CR39">39</xref>]. This classification has been transferred in clinical practice to describe the resectability of pNETs in the pancreatic head [<xref ref-type="bibr" rid="CR5">5</xref>]. The advancements in pancreatic surgery in the last decades have resulted in an increased number of patients being eligible for tumour resection and higher rates of R0 resection [<xref ref-type="bibr" rid="CR40">40</xref>]. Portal vein resection and reconstruction (PVR) has become a standard procedure in pancreatic centres [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par19">Major vessel involvement occurs in up to 17% of pNETs [<xref ref-type="bibr" rid="CR43">43</xref>]. Based on the advancements in PDAC resection, PVR has been applied to locally advanced pNETs alike, however, data on oncologic benefit of these procedure remain scarce. Involvement of the SMV in locally advanced pNETs is not considered irresectable per se, if vascular resection is technically manageable and if no vein occlusion is present [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par20">Recently, three larger studies on pancreatic resection with PVR have been published [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]: Nie&#x000df;en et al., Fusai et al. and Gudmundsdottir et al. found no significant difference in postoperative complication rates as well as comparable overall- and disease-free survival after PVR compared to standard resection for pNETs after propensity-score matching. As expected, all observed higher blood loss and longer operation times when PVR was conducted [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Importantly, PVR is associated with the risk of developing portal vein thrombosis, especially when venous allografts are necessary (ISGPS Type IV reconstruction) [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. This type of reconstruction should thus be avoided whenever feasible. Close monitoring of postoperative liver perfusion is mandatory after these procedures, especially when an allograft was necessary [<xref ref-type="bibr" rid="CR41">41</xref>]. There is no data on the recommended mode and duration of anticoagulation after PVR and each centre follows its own protocol [<xref ref-type="bibr" rid="CR44">44</xref>]. In selected cases, PVR may even be performed robotically (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Intraoperative image of robotic portal vein resection (<bold>A</bold> and <bold>B</bold>) and Type II reconstruction (<bold>C</bold> and <bold>D</bold>) using a bovine pericardial patch. The figure is adapted from Kulu , Y. , Contin , P. , Hackert , T. (2021). Pankreaschirurgie. In: Hackert , T. , Croner , R.S. (eds) Roboterassistierte Viszeral- und Thoraxchirurgie. Springer , Berlin , Heidelberg. Figure 4.10; p. 41 [German]</p></caption><graphic xlink:href="11912_2024_1632_Fig2_HTML" id="MO2"/></fig></p><p id="Par21">Taken together, resection and PVR of locally advanced pNETs with portal vein involvement may be considered in selected patients. However, the conduction of such advanced procedures should be limited to experienced centres and only be conducted after interdisciplinary and thorough discussion with the individual patient [<xref ref-type="bibr" rid="CR5">5</xref>].</p></sec><sec id="Sec7"><title>Primary Tumour Resection in Case of Distant Metastasis</title><p id="Par22">For localised and locally advanced pNETs, primary tumour resection &#x02013; with resection of potential metastasis &#x02013; is the treatment of choice [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. However, the benefit of primary tumour resection in case of distant metastasis remains ambiguous. Previously, only small studies evaluating the benefit of primary tumour resection were available [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Recently, two larger studies retrospectively evaluated the benefit of primary tumour resection for stage IV pNETs. They could both show a benefit in overall survival for patients undergoing primary tumour resections [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par23">Thus, primary tumour resection should be considered for stage IV pNETs, who are fit enough for surgery to reduce tumour burden and thereby potentially improve survival. However, prospective data on resection of stage IV pNETs is lacking [<xref ref-type="bibr" rid="CR51">51</xref>]. Also, the potential benefit of neoadjuvant treatment, i.e. with PRRT, in order to enable a secondary resecability of advanced pNETs remains unclear [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par24">The novel surgical approaches of pNETs are summarized in Fig. <xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><p>Schematic display of current indications for surgical resection of pancreatic, small intestinal and appendiceal neuroendocrine tumours. nf-pNET: non-functioning pancreatic neuroendocrine tumour. The figure was created in BioRender. Ritter , A. (2024) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/z45h674">https://BioRender.com/z45h674</ext-link></p></caption><graphic xlink:href="11912_2024_1632_Fig3_HTML" id="MO3"/></fig></p></sec></sec><sec id="Sec8"><title>Small Intestinal NETs &#x02013; How Should We Resect?</title><sec id="Sec9"><title>Retrograde Vessel-Sparing Lymphadenectomy for Small-Intestinal NETs</title><p id="Par25">The small intestine in the most frequent localisation of NETs in the gastrointestinal tract [<xref ref-type="bibr" rid="CR1">1</xref>]. While usually small and slowly proliferating, small intestinal NETs (siNETs) are frequently locally advanced or metastasised to regional lymph nodes or the liver at the time of primary diagnosis [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Mesenteric lymph node metastasis can exceed the primary tumour in size and cause desmoplastic fibrosis, resulting in shrinkage of the mesentery [<xref ref-type="bibr" rid="CR57">57</xref>]. This can cause abdominal pain, initiating a diagnostic work up in the first place or result in acute bowel obstruction, mesenteric ischemia or bleeding requiring emergency surgery [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par26">The standard of care for siNETs located&#x02009;&#x0003e;&#x02009;20 cm orally of the ileocolic valve is the resection of the primary tumour as well as a systematic lymphadenectomy along the mesenteric vessels. This used to result in the resection of a &#x0201c;pizza pie&#x0201d;-shaped bowel segment with the adjacent mesenteric soft tissue [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. A minimum of eight lymph nodes should be harvested to improve oncologic outcome. Recently, a newer study even suggested a minimum of 12 lymph nodes [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. However, due to the possibility of multifocal primary tumour localisation, local advancement of the primary tumour or central mesenteric lymph node metastases and their proximity to the intestinal blood vessels, extensive small bowel resection can be necessary to achieve a R0 resection. This puts the patient at risk of developing short bowel syndrome, resulting in malnutrition and diarrhoea and necessitating parenteral nutrition [<xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par27">However, recent studies have shown that the length of the resected small bowel segment does not correlate with the number of lymph nodes harvested and lymph node metastases can skip in between lymph node levels [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. This has resulted in the proposal of &#x0201c;retrograde vessel-sparing lymphadenectomy&#x0201d; (VS-LA) in order to reduce the length of resected intestine, without sacrificing oncologic radicality [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Technically, this is achieved by longitudinally incising the peritoneum along the SMA below the horizontal duodenum or pancreatic body and removing the adjacent soft tissue. Subsequently, retrograde dissection of the lymphatic tissue around the main mesenteric artery and vein distally of the tumour, while preserving ileocolic vessels, vascular collaterals and arcades along the intestine. Finally, the tumour affected bowel segment is resected as a last step [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par28">A retrospective study comparing 25 patients with conventional vs. 25 with VS-LA showed, that shorter small bowel segments were resected in the VS-LA group, (40&#x000a0;(11-65)&#x000a0;vs. 65 (23-190) cm), while the number of harvested lymph nodes as well as R0 resections were comparable. Severe postoperative complications (Clavien-Dindo&#x02009;&#x02265;&#x02009;3), postoperative abdominal pain was less frequent in the VS-LA group. No local recurrence was observed in either group, however, long-term follow up was significantly shorter in the VS-LA group (24 (3&#x02013;91) vs. 63 (6&#x02013;94) months) [<xref ref-type="bibr" rid="CR65">65</xref>]. Thus far, no larger studies are available to further evaluate the potential benefit of this resection technique [<xref ref-type="bibr" rid="CR7">7</xref>].</p></sec><sec id="Sec10"><title>Right-Sided Hemicolectomy for NETs in the Distal Ileum</title><p id="Par29">For NETs located proximally to the ileocolic valve, it remains controversial, when segmental bowel resection or formal right-sided hemicolectomy should be performed [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Interestingly, a study by Li et al. compared 93 patients receiving right hemicolectomy with 34 patients undergoing ileocecal resection for NETs in the distal ileum. While the number of harvested lymph nodes was significantly lower after ileocecal resection (17 vs. 14) - yet above the recommended minimum number of 8 &#x02013; overall- (OS) and disease-free (DFS) survival did not significantly differ [<xref ref-type="bibr" rid="CR67">67</xref>]. In contrast, Evers et al. found a right-sided hemicolectomy to be significantly associated with higher DFS in siNET patients [<xref ref-type="bibr" rid="CR68">68</xref>].</p><p id="Par30">Thus, even the most current ENETS guidelines for siNETs within 20 cm orally to the ileocolic valve still recommend either procedure depending on individual risk factors [<xref ref-type="bibr" rid="CR7">7</xref>].</p></sec><sec id="Sec11"><title>Minimally Invasive Surgery for Small Intestinal NETs</title><p id="Par31">The invention and further expansion of MIS has probably been the biggest paradigm-shifting development in surgical practice in the last 50 years. It is associated with reduced postoperative pain, shorter hospital stay and faster return to everyday life [<xref ref-type="bibr" rid="CR69">69</xref>]. While MIS has gained wide acceptance for many procedures, laparoscopic resection of siNETs remains controversial and ENETS and NANTES guidelines recommend laparoscopic resection of siNETs in selected cases only [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Disadvantages of MIS in the context of siNETs are the inability to perform bimanual palpation of the entire intestine &#x02013; thereby missing potential multifocal tumour growth &#x02013;, confined exposure of the abdominal cavity &#x02013; thereby overseeing occult peritoneal lesions &#x02013; and the restricted vascular control when performing central mesenteric lymphadenectomy &#x02013; thereby performing less radical lymphadenectomy. Additionally, the presence of mesenteric fibrosis as well as acute intestinal obstruction, bleeding or ischemia may deem the patient unsuitable for laparoscopic resection [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par32">Despite these potential obstacles, laparoscopic resection of siNETs has been increasingly conducted in high-volume centres: The lymph node yield may be either equal or even higher in the laparoscopically resected siNETs [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. However, reported conversion rates range from 17.7 to 30% [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. As for other procedures, minimally invasive resection of siNETs was associated with a shorter hospital stay and a reduced rate of unplanned readmissions [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Importantly, long term oncological outcomes reported so far, have been comparable between laparoscopic and open resection of siNETs [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par33">Thus, MIS or hand-assisted MIS for siNETs is increasingly performed in experienced centres in elective settings taking into account the risk of intraoperative conversion especially in advanced tumour stages.</p></sec><sec id="Sec12"><title>Intraoperative Tumour Localization of Small Intestinal NETs</title><p id="Par34">One of the unsolved problems in the diagnostics of siNETs and thus also the possibility of MIS, is the difficulty to achieve preoperative tumour localisation: Only siNETs in the very distal ileum can be visualized by colonoscopy. Additionally, primary tumour size is often below the resolution threshold of CT and MRI scans, which is further distorted by motion artefacts due to small intestinal peristalsis. Simultaneously, approximately 40&#x02013;60% of siNETs grow multifocally and even primary tumours&#x02009;&#x0003c;&#x02009;1 cm can cause lymph node metastasis [<xref ref-type="bibr" rid="CR7">7</xref>]. Thus, bimanual palpation of the entire intestine remains the recommended diagnostic strategy [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par35">An approach to overcome these diagnostic challenges are intraoperative tumour visualization tools: Indocyanine green (ICG) is an easy to use, safe and widely available dye to perform intraoperative visualization; it illuminates at the excitation wavelength (about 750 to 800 nm) while emission wavelengths (over 800 nm) can be observed [<xref ref-type="bibr" rid="CR74">74</xref>]. ICG can be used to visualize bowel perfusion intraoperatively. In the context of siNETs, this can either enable bowel sparing-resections as well as to prevent anastomotic reconstruction within a malperfused bowel segment [<xref ref-type="bibr" rid="CR75">75</xref>]. Additionally, ICG can visualize superficial liver metastasis as well as facilitate R0 resections in parenchyma-sparing liver resections [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Likewise, ICG has successfully been used in the localisation of pNETs [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par36">An alternative approach to intraoperative tumour localization is near-infrared fluorescence autofluorescence (NIRAF). NIRAF was first discovered in parathyroid glands, which emit an autofluorescence signal when excited with a 785 nm wavelength laser [<xref ref-type="bibr" rid="CR78">78</xref>]. A small feasibility study has applied NIRAF in siNET patients: The autofluorescence intensity of siNETs was significantly higher than the one of healthy small bowel and it was superior to DOTATATE-PET/CT and bimanual palpation in the detection of siNET primary tumours [<xref ref-type="bibr" rid="CR76">76</xref>]. However, the benefit of NIRAF for detection of lymph node and peritoneal metastases was limited.</p><p id="Par37">Radio-guided surgery is another approach using radioactive probes to localize tumours intraoperatively: In the context of siNETs, the expression of somatostatin receptors can be exploited using 68Ga-DOTATATE labelled probes to facilitate the localisation of primary siNETs as well as lymph node metastasis [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. Due to the obvious logistical efforts using radioactive tracer substances, this procedure has not gained widespread acceptance so far.</p><p id="Par38">All mentioned approaches to improve intraoperative tumour localisation of GEP-NETs have been evaluated, however, currently experiences are still limited to small feasibility studies. The use of these detection tools still need validation in larger cohorts before any of these become widely applied in clinical practice.</p><p id="Par39">The recent surgical advancements in siNETs are displayed in Fig. <xref rid="Fig3" ref-type="fig">3</xref>.</p></sec></sec><sec id="Sec13"><title>Appendiceal NETs &#x02013; Are We Overtreating?</title><sec id="Sec14"><title>Omitting of Right-Sided Hemicolectomy for Appendiceal-NETs&#x02009;&#x0003c;&#x02009;2 cm?</title><p id="Par40">Appendiceal neuroendocrine tumours (aNETs) are found incidentally after about 1.5% of all appendectomies with a yearly incidence of 0.15&#x02013;0.6 per 100.000 [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Current ENETS guidelines recommend simple appendectomy for aNETs&#x02009;&#x0003c;&#x02009;1 cm and oncological right-sided hemicolectomy for tumours&#x02009;&#x0003e;&#x02009;2 cm [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. However, there is still a controversy regarding the adequate extent of operation of aNETs 1&#x02013;2 cm in size. Currently, positive or unclear resection margins, deep mesoappendiceal invasion&#x02009;&#x0003e;&#x02009;3 mm, high proliferation rate (G2), vascular (V1) or lymphatic vessel invasion (L1) are considered risk factors for lymph node metastasis and would thus necessitate a right hemicolectomy with lymph node dissection [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. However, recent studies have challenged this recommendation, resulting in potential overtreatment of the intermediate risk group [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>].</p><p id="Par41">A recent European retrospective, multi-centre study has compared 278 patients with aNETs between 1 and 2 cm, 163 of which were treated with an appendectomy and 115 with oncological right-sided hemicolectomy [<xref ref-type="bibr" rid="CR89">89</xref>]. No differences were found in long-term survival between the two groups, suggesting that right-sided hemicolectomy may be omitted for aNETs&#x02009;&#x02264;&#x02009;2 cm [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. No patient developed metachronous, distant metastasis of aNET in either group [<xref ref-type="bibr" rid="CR89">89</xref>]. Thus, the indication for right-sided hemicolectomy might be re-evaluated in future NET guidelines.</p></sec></sec><sec id="Sec15"><title>Conclusions</title><p id="Par42">Surgery remains the most common treatment and only potential cure for GEP-NETs, however, when and how to operate on GEP-NETs has undergone substantial shifts in the last years. While for some entities a watch-and-wait approach or less radical surgery may be justified, evolution in surgical techniques also allow for locally advanced NETs to be resected in selected patients. Simultaneously, novel techniques such as minimal invasive and robot-assisted surgery, intraoperative imaging tools and vessel-sparing resections, reduce collateral tissue damage while maintaining appropriate oncologic radicality.</p><p id="Par43">Surgical guidelines and techniques for resections of GEP-NETs need to be continuously challenged and revisited in order to continuously provide optimal interdisciplinary care for GEP-NET patients at specialised centres.</p><sec id="Sec16"><title>Key References</title><p id="Par44">
<list list-type="bullet"><list-item><p id="Par45">Partelli S, Massironi S, Zerbi A, Niccoli P, Kwon W, Landoni L, et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial. Br J Surg. 2022;109 (12):1186-90.<list list-type="bullet"><list-item><p id="Par46">This is an interim analysis of the largest multicentre, non-randomised, prospective trial that determines the outcome of resection versus active surveillance in small nf-pNETs.</p></list-item></list></p></list-item><list-item><p id="Par47">Heidsma CM, Engelsman AF, van Dieren S, Stommel MWJ, de Hingh I, Vriens M, et al. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). British Journal of Surgery. 2021;108 (8):888&#x02009;&#x02212;&#x02009;91.<list list-type="bullet"><list-item><p id="Par48">This is an interim analysis of a large, prospective cohort study in the Netherlands evaluating the safety of a watch-and-wait approach in patients with nf-pNETs&#x02009;&#x02264;&#x02009;2 cm.</p></list-item></list></p></list-item><list-item><p id="Par49">Klotz R, Mihaljevic AL, Kulu Y, Sander A, Klose C, Behnisch R, et al. Robotic versus open partial pancreatoduodenectomy (EUROPA): a randomised controlled stage 2b trial. Lancet Reg Health Eur. 2024;39:100864.<list list-type="bullet"><list-item><p id="Par50">This is the first randomised controlled trial comparing short-term outcomes of robotic versus open partial pancreaticoduodenectomy.</p></list-item></list></p></list-item><list-item><p id="Par51">Korrel M, Jones LR, van Hilst J, Balzano G, Bj&#x000f6;rnsson B, Boggi U, et al. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Lancet Reg Health Eur. 2023;31:100673.<list list-type="bullet"><list-item><p id="Par52">This is the first randomised controlled trial showing that minimally invasive distal pancreatectomy is not inferior to open resection.</p></list-item></list></p></list-item><list-item><p id="Par53">Zheng J, Pulvirenti A, Javed AA, Michelakos T, Paniccia A, Lee KK, et al. Minimally Invasive vs. Open Pancreatectomy for Pancreatic Neuroendocrine Tumors: Multi-Institutional 10-Year Experience of 1,023 Patients. J Am Coll Surg. 2022;235(2):315&#x02009;&#x02212;&#x02009;30.<list list-type="bullet"><list-item><p id="Par54">This is the largest mulicentre study retropectively comparing perioperative and long-term outcomes after minimally invasive and open resection of pNETs.</p></list-item></list></p></list-item><list-item><p id="Par55">Nie&#x000df;en A, Klaiber U, Lewosinska M, Nickel F, Billmann F, Hinz U, et al. Portal vein resection in pancreatic neuroendocrine neoplasms. Surgery. 2024;175(4):1154-61.<list list-type="bullet"><list-item><p id="Par56">This is the largest retrospective single-centre analysis reporting on short- and long-term results after portal vein resection for locally advanced pNETs.</p></list-item></list></p></list-item><list-item><p id="Par57">Gudmundsdottir H, Tomlinson JL, Graham RP, Thiels CA, Warner SG, Smoot RL, et al. Outcomes of pancreatectomy with portomesenteric venous resection and reconstruction for locally advanced pancreatic neuroendocrine neoplasms. HPB (Oxford). 2022;24 (7):1186-93.<list list-type="bullet"><list-item><p id="Par58">This is one of the first retrospective analyses reporting on the outcome after portal vein resection in locally advanced pNETs.</p></list-item></list></p></list-item><list-item><p id="Par59">Kaslow SR, Hani L, Cohen SM, Wolfgang CL, Sacks GD, Berman RS, et al. Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: An analysis of the National Cancer Database. Journal of Surgical Oncology. 2023;128 (2):262&#x02009;&#x02212;&#x02009;70.<list list-type="bullet"><list-item><p id="Par60">This is the largest retrospective cohort study evaluating the benefit of primary tumor resection in patients with metastatic pNET.</p></list-item></list></p></list-item><list-item><p id="Par61">Bartsch DK, Windel S, Kanngie&#x000df;er V, Jesinghaus M, Holzer K, Rinke A, et al. Vessel-Sparing Lymphadenectomy Should Be Performed in Small Intestine Neuroendocrine Neoplasms. Cancers (Basel). 2022;14(15).<list list-type="bullet"><list-item><p id="Par62">This study retrospectively compared retrograde vessel-sparing lymphadenectomy with conventional resection of siNETs. A comparable amout of lymph nodes harvested, but less small bowel resected was observed when applying this novel technique.</p></list-item></list></p></list-item><list-item><p id="Par63">Li MX, Lopez-Aguiar AG, Poultsides G, Rocha F, Weber S, Fields R, et al. Surgical Treatment of Neuroendocrine Tumors of the Terminal Ileum or Cecum: Ileocecectomy Versus Right Hemicolectomy. J Gastrointest Surg. 2022;26(6):1266-74.<list list-type="bullet"><list-item><p id="Par64">This study compared the long-term oncologic outcomes after right-sided hemicolectomy and ileocecectomy for siNETs of the terminal ileum and found similar survival rates despite a lower lymph node harvest after ileocecectomy.</p></list-item></list></p></list-item><list-item><p id="Par65">Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, et al. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. Ann Surg Oncol. 2024;31 (9):5507-14.<list list-type="bullet"><list-item><p id="Par66">This study evaluated the overall survival after minimally invasive vs. open resection of ileal NETs and found similar long-term outcomes.</p></list-item></list></p></list-item><list-item><p id="Par67">Nesti C, Br&#x000e4;utigam K, Benavent M, Bernal L, Boharoon H, Botling J, et al. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1&#x02013;2 cm in size: a retrospective, Europe-wide, pooled cohort study. Lancet Oncol. 2023;24 (2):187&#x02009;&#x02212;&#x02009;94.<list list-type="bullet"><list-item><p id="Par68">This is the largest study comparing right-sided hemicolectomy with appendectomy for appendix NETs of intermeditate sizes (1&#x02013;2 cm).</p></list-item></list></p></list-item></list>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contributions</title><p>Writing &#x02013; original draft preparation: A.S.R. and A.N.; validation and visualization: A.S.R., J.P., K.C.S., T.H. and A.N.; writing&#x02014;review and&#x000a0;editing: A.S.R., J.P., K.C.S., T.H. and A.N.. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL. This research received no specific grant from public, commercial, or not-for-profit funding agencies. The authors report no relevant financial relationships.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par69">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Human and Animal Rights</title><p id="Par70">This article does not contain any studies with human or animal subjects performed by any of the authors.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Dasari</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Halperin</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States</article-title><source>JAMA Oncol</source><year>2017</year><volume>3</volume><issue>10</issue><fpage>1335</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">28448665</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335&#x02013;42.<pub-id pub-id-type="pmid">28448665</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Borbath</surname><given-names>I</given-names></name><name><surname>Garcia-Carbonero</surname><given-names>R</given-names></name><name><surname>Bikmukhametov</surname><given-names>D</given-names></name><name><surname>Jimenez-Fonseca</surname><given-names>P</given-names></name><name><surname>Casta&#x000f1;o</surname><given-names>A</given-names></name><name><surname>Barkmanova</surname><given-names>J</given-names></name><etal/></person-group><article-title>The European neuroendocrine tumour society registry, a tool to assess the prognosis of neuroendocrine neoplasms</article-title><source>Eur J Cancer</source><year>2022</year><volume>168</volume><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">35472579</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Borbath I, Garcia-Carbonero R, Bikmukhametov D, Jimenez-Fonseca P, Casta&#x000f1;o A, Barkmanova J, et al. The European neuroendocrine tumour society registry, a tool to assess the prognosis of neuroendocrine neoplasms. Eur J Cancer. 2022;168:80&#x02013;90.<pub-id pub-id-type="pmid">35472579</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Howe</surname><given-names>JR</given-names></name><name><surname>Cardona</surname><given-names>K</given-names></name><name><surname>Fraker</surname><given-names>DL</given-names></name><name><surname>Kebebew</surname><given-names>E</given-names></name><name><surname>Untch</surname><given-names>BR</given-names></name><name><surname>Wang</surname><given-names>YZ</given-names></name><etal/></person-group><article-title>The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the north american neuroendocrine tumor society</article-title><source>Pancreas</source><year>2017</year><volume>46</volume><issue>6</issue><fpage>715</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">28609357</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the north american neuroendocrine tumor society. Pancreas. 2017;46(6):715&#x02013;31.<pub-id pub-id-type="pmid">28609357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Howe</surname><given-names>JR</given-names></name><name><surname>Merchant</surname><given-names>NB</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Keutgen</surname><given-names>XM</given-names></name><name><surname>Hallet</surname><given-names>J</given-names></name><name><surname>Drebin</surname><given-names>JA</given-names></name><etal/></person-group><article-title>The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors</article-title><source>Pancreas</source><year>2020</year><volume>49</volume><issue>1</issue><fpage>1</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">31856076</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1&#x02013;33.<pub-id pub-id-type="pmid">31856076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Kos-Kud&#x00142;a</surname><given-names>B</given-names></name><name><surname>Casta&#x000f1;o</surname><given-names>JP</given-names></name><name><surname>Denecke</surname><given-names>T</given-names></name><name><surname>Grande</surname><given-names>E</given-names></name><name><surname>Kjaer</surname><given-names>A</given-names></name><name><surname>Koumarianou</surname><given-names>A</given-names></name><etal/></person-group><article-title>European neuroendocrine tumour society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours</article-title><source>J Neuroendocrinol</source><year>2023</year><volume>35</volume><issue>12</issue><fpage>e13343</fpage><pub-id pub-id-type="pmid">37877341</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kos-Kud&#x00142;a B, Casta&#x000f1;o JP, Denecke T, Grande E, Kjaer A, Koumarianou A, et al. European neuroendocrine tumour society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35(12):e13343.<pub-id pub-id-type="pmid">37877341</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Hofland</surname><given-names>J</given-names></name><name><surname>Falconi</surname><given-names>M</given-names></name><name><surname>Christ</surname><given-names>E</given-names></name><name><surname>Casta&#x000f1;o</surname><given-names>JP</given-names></name><name><surname>Faggiano</surname><given-names>A</given-names></name><name><surname>Lamarca</surname><given-names>A</given-names></name><etal/></person-group><article-title>European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes</article-title><source>J Neuroendocrinol</source><year>2023</year><volume>35</volume><issue>8</issue><fpage>e13318</fpage><pub-id pub-id-type="pmid">37578384</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Hofland J, Falconi M, Christ E, Casta&#x000f1;o JP, Faggiano A, Lamarca A, et al. European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318.<pub-id pub-id-type="pmid">37578384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Lamarca</surname><given-names>A</given-names></name><name><surname>Bartsch</surname><given-names>DK</given-names></name><name><surname>Caplin</surname><given-names>M</given-names></name><name><surname>Kos-Kudla</surname><given-names>B</given-names></name><name><surname>Kjaer</surname><given-names>A</given-names></name><name><surname>Partelli</surname><given-names>S</given-names></name><etal/></person-group><article-title>European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours</article-title><source>J Neuroendocrinol</source><year>2024</year><volume>36</volume><issue>9</issue><fpage>e13423</fpage><pub-id pub-id-type="pmid">38977327</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Lamarca A, Bartsch DK, Caplin M, Kos-Kudla B, Kjaer A, Partelli S, et al. European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024;36(9):e13423.<pub-id pub-id-type="pmid">38977327</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaltsas</surname><given-names>G</given-names></name><name><surname>Walter</surname><given-names>T</given-names></name><name><surname>Knigge</surname><given-names>U</given-names></name><name><surname>Toumpanakis</surname><given-names>C</given-names></name><name><surname>Santos</surname><given-names>AP</given-names></name><name><surname>Begum</surname><given-names>N</given-names></name><etal/></person-group><article-title>European neuroendocrine tumor society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET)</article-title><source>J Neuroendocrinol</source><year>2023</year><volume>35</volume><issue>10</issue><fpage>e13332</fpage><pub-id pub-id-type="pmid">37682701</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Kaltsas G, Walter T, Knigge U, Toumpanakis C, Santos AP, Begum N, et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET). J Neuroendocrinol. 2023;35(10):e13332.<pub-id pub-id-type="pmid">37682701</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Rinke</surname><given-names>A</given-names></name><name><surname>Ambrosini</surname><given-names>V</given-names></name><name><surname>Dromain</surname><given-names>C</given-names></name><name><surname>Garcia-Carbonero</surname><given-names>R</given-names></name><name><surname>Haji</surname><given-names>A</given-names></name><name><surname>Koumarianou</surname><given-names>A</given-names></name><etal/></person-group><article-title>European neuroendocrine tumor society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours</article-title><source>J Neuroendocrinol</source><year>2023</year><volume>35</volume><issue>6</issue><fpage>e13309</fpage><pub-id pub-id-type="pmid">37345509</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A, et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol. 2023;35(6):e13309.<pub-id pub-id-type="pmid">37345509</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Panzuto</surname><given-names>F</given-names></name><name><surname>Ramage</surname><given-names>J</given-names></name><name><surname>Pritchard</surname><given-names>DM</given-names></name><name><surname>van Velthuysen</surname><given-names>M-LF</given-names></name><name><surname>Schrader</surname><given-names>J</given-names></name><name><surname>Begum</surname><given-names>N</given-names></name><etal/></person-group><article-title>European neuroendocrine tumor society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1&#x02013;G3</article-title><source>J Neuroendocrinol</source><year>2023</year><volume>35</volume><issue>8</issue><fpage>e13306</fpage><pub-id pub-id-type="pmid">37401795</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Panzuto F, Ramage J, Pritchard DM, van Velthuysen M-LF, Schrader J, Begum N, et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1&#x02013;G3. J Neuroendocrinol. 2023;35(8):e13306.<pub-id pub-id-type="pmid">37401795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>MB</given-names></name><name><surname>Almquist</surname><given-names>M</given-names></name><name><surname>Bergenfelz</surname><given-names>A</given-names></name><name><surname>Nordenstr&#x000f6;m</surname><given-names>E</given-names></name></person-group><article-title>Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias</article-title><source>Langenbeck&#x02019;s Archives Surg</source><year>2020</year><volume>405</volume><issue>2</issue><fpage>137</fpage><lpage>43</lpage></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Albers MB, Almquist M, Bergenfelz A, Nordenstr&#x000f6;m E. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias. Langenbeck&#x02019;s Archives Surg. 2020;405(2):137&#x02013;43.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Partelli</surname><given-names>S</given-names></name><name><surname>Bartsch</surname><given-names>DK</given-names></name><name><surname>Capdevila</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Knigge</surname><given-names>U</given-names></name><name><surname>Niederle</surname><given-names>B</given-names></name><etal/></person-group><article-title>ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours</article-title><source>Neuroendocrinology</source><year>2017</year><volume>105</volume><issue>3</issue><fpage>255</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">28237989</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2017;105(3):255&#x02013;65.<pub-id pub-id-type="pmid">28237989</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Assi</surname><given-names>HA</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Kunz</surname><given-names>PL</given-names></name><name><surname>Machiorlatti</surname><given-names>M</given-names></name><name><surname>Vesely</surname><given-names>S</given-names></name><name><surname>Pareek</surname><given-names>V</given-names></name><etal/></person-group><article-title>Surgery versus surveillance for well-differentiated, nonfunctional pancreatic neuroendocrine tumors: an 11-year analysis of the national cancer database</article-title><source>Oncologist</source><year>2020</year><volume>25</volume><issue>2</issue><fpage>e276</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">32043766</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, et al. Surgery versus surveillance for well-differentiated, nonfunctional pancreatic neuroendocrine tumors: an 11-year analysis of the national cancer database. Oncologist. 2020;25(2):e276-83.<pub-id pub-id-type="pmid">32043766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Partelli</surname><given-names>S</given-names></name><name><surname>Massironi</surname><given-names>S</given-names></name><name><surname>Zerbi</surname><given-names>A</given-names></name><name><surname>Niccoli</surname><given-names>P</given-names></name><name><surname>Kwon</surname><given-names>W</given-names></name><name><surname>Landoni</surname><given-names>L</given-names></name><etal/></person-group><article-title>Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2&#x000a0;cm: interim analysis of prospective ASPEN trial</article-title><source>Br J Surg</source><year>2022</year><volume>109</volume><issue>12</issue><fpage>1186</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">35986682</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Partelli S, Massironi S, Zerbi A, Niccoli P, Kwon W, Landoni L, et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2&#x000a0;cm: interim analysis of prospective ASPEN trial. Br J Surg. 2022;109(12):1186&#x02013;90.<pub-id pub-id-type="pmid">35986682</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Heidsma</surname><given-names>CM</given-names></name><name><surname>Engelsman</surname><given-names>AF</given-names></name><name><surname>van Dieren</surname><given-names>S</given-names></name><name><surname>Stommel</surname><given-names>MWJ</given-names></name><name><surname>de Hingh</surname><given-names>I</given-names></name><name><surname>Vriens</surname><given-names>M</given-names></name><etal/></person-group><article-title>Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA)</article-title><source>Br J Surg</source><year>2021</year><volume>108</volume><issue>8</issue><fpage>888</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">33783475</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Heidsma CM, Engelsman AF, van Dieren S, Stommel MWJ, de Hingh I, Vriens M, et al. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). Br J Surg. 2021;108(8):888&#x02013;91.<pub-id pub-id-type="pmid">33783475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Chivukula</surname><given-names>SV</given-names></name><name><surname>Tierney</surname><given-names>JF</given-names></name><name><surname>Hertl</surname><given-names>M</given-names></name><name><surname>Poirier</surname><given-names>J</given-names></name><name><surname>Keutgen</surname><given-names>XM</given-names></name></person-group><article-title>Operative resection in early stage pancreatic neuroendocrine tumors in the United States: are we over- or undertreating patients?</article-title><source>Surgery</source><year>2020</year><volume>167</volume><issue>1</issue><fpage>180</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">31537303</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chivukula SV, Tierney JF, Hertl M, Poirier J, Keutgen XM. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: are we over- or undertreating patients? Surgery. 2020;167(1):180&#x02013;6.<pub-id pub-id-type="pmid">31537303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Nie&#x000df;en A, Bechtiger FA, Hinz U, Lewosinska M, Billmann F, Hackert T, et al. Enucleation is a feasible procedure for well-differentiated pNEN-A matched pair analysis. Cancers (Basel). 2022;14(10).</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehrabi</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>L</given-names></name><name><surname>Hafezi</surname><given-names>M</given-names></name><name><surname>Dirlewanger</surname><given-names>A</given-names></name><name><surname>Grenacher</surname><given-names>L</given-names></name><name><surname>Diener</surname><given-names>MK</given-names></name><etal/></person-group><article-title>A systematic review of localization, surgical treatment options, and outcome of insulinoma</article-title><source>Pancreas</source><year>2014</year><volume>43</volume><issue>5</issue><fpage>675</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">24921202</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Mehrabi A, Fischer L, Hafezi M, Dirlewanger A, Grenacher L, Diener MK, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43(5):675&#x02013;86.<pub-id pub-id-type="pmid">24921202</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>de Carbonni&#x000e8;res</surname><given-names>A</given-names></name><name><surname>Challine</surname><given-names>A</given-names></name><name><surname>Cottereau</surname><given-names>AS</given-names></name><name><surname>Coriat</surname><given-names>R</given-names></name><name><surname>Soyer</surname><given-names>P</given-names></name><name><surname>Abou Ali</surname><given-names>E</given-names></name><etal/></person-group><article-title>Surgical management of insulinoma over three decades</article-title><source>HPB (Oxford)</source><year>2021</year><volume>23</volume><issue>12</issue><fpage>1799</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">33975801</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">de Carbonni&#x000e8;res A, Challine A, Cottereau AS, Coriat R, Soyer P, Abou Ali E, et al. Surgical management of insulinoma over three decades. HPB (Oxford). 2021;23(12):1799&#x02013;806.<pub-id pub-id-type="pmid">33975801</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Beane</surname><given-names>JD</given-names></name><name><surname>Borrebach</surname><given-names>JD</given-names></name><name><surname>Billderback</surname><given-names>A</given-names></name><name><surname>Onuma</surname><given-names>AE</given-names></name><name><surname>Adam</surname><given-names>MA</given-names></name><name><surname>Zureikat</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Small pancreatic neuroendocrine tumors: resect or enucleate?</article-title><source>Am J Surg</source><year>2021</year><volume>222</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">33317810</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Beane JD, Borrebach JD, Billderback A, Onuma AE, Adam MA, Zureikat AH, et al. Small pancreatic neuroendocrine tumors: resect or enucleate? Am J Surg. 2021;222(1):29&#x02013;34.<pub-id pub-id-type="pmid">33317810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000fc;ttner</surname><given-names>FJ</given-names></name><name><surname>Koessler-Ebs</surname><given-names>J</given-names></name><name><surname>Hackert</surname><given-names>T</given-names></name><name><surname>Ulrich</surname><given-names>A</given-names></name><name><surname>B&#x000fc;chler</surname><given-names>MW</given-names></name><name><surname>Diener</surname><given-names>MK</given-names></name></person-group><article-title>Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms</article-title><source>Br J Surg</source><year>2015</year><volume>102</volume><issue>9</issue><fpage>1026</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">26041666</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">H&#x000fc;ttner FJ, Koessler-Ebs J, Hackert T, Ulrich A, B&#x000fc;chler MW, Diener MK. Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms. Br J Surg. 2015;102(9):1026&#x02013;36.<pub-id pub-id-type="pmid">26041666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Si</surname><given-names>X</given-names></name></person-group><article-title>Short- and long-term outcomes after enucleation of pancreatic tumors: an evidence-based assessment</article-title><source>Pancreatology</source><year>2016</year><volume>16</volume><issue>6</issue><fpage>1092</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27423534</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zhou Y, Zhao M, Wu L, Ye F, Si X. Short- and long-term outcomes after enucleation of pancreatic tumors: an evidence-based assessment. Pancreatology. 2016;16(6):1092&#x02013;8.<pub-id pub-id-type="pmid">27423534</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Nie&#x000df;en</surname><given-names>A</given-names></name><name><surname>Schimmack</surname><given-names>S</given-names></name><name><surname>Lewosinska</surname><given-names>M</given-names></name><name><surname>Hinz</surname><given-names>U</given-names></name><name><surname>Bechtiger</surname><given-names>FA</given-names></name><name><surname>Hackert</surname><given-names>T</given-names></name><etal/></person-group><article-title>Lymph node metastases and recurrence in pancreatic neuroendocrine neoplasms</article-title><source>Surgery</source><year>2022</year><volume>172</volume><issue>6</issue><fpage>1791</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">36180252</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Nie&#x000df;en A, Schimmack S, Lewosinska M, Hinz U, Bechtiger FA, Hackert T, et al. Lymph node metastases and recurrence in pancreatic neuroendocrine neoplasms. Surgery. 2022;172(6):1791&#x02013;9.<pub-id pub-id-type="pmid">36180252</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Prognostic value and clinical predictors of Lymph Node metastases in pancreatic neuroendocrine tumors</article-title><source>Pancreas</source><year>2020</year><volume>49</volume><issue>3</issue><fpage>381</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">32132507</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zhang Z, Liu M, Ji S, Luo G, Xu W, Liu W, et al. Prognostic value and clinical predictors of Lymph Node metastases in pancreatic neuroendocrine tumors. Pancreas. 2020;49(3):381&#x02013;6.<pub-id pub-id-type="pmid">32132507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Partelli</surname><given-names>S</given-names></name><name><surname>Gaujoux</surname><given-names>S</given-names></name><name><surname>Boninsegna</surname><given-names>L</given-names></name><name><surname>Cherif</surname><given-names>R</given-names></name><name><surname>Crippa</surname><given-names>S</given-names></name><name><surname>Couvelard</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs)</article-title><source>JAMA Surg</source><year>2013</year><volume>148</volume><issue>10</issue><fpage>932</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23986355</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Partelli S, Gaujoux S, Boninsegna L, Cherif R, Crippa S, Couvelard A, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). JAMA Surg. 2013;148(10):932&#x02013;9.<pub-id pub-id-type="pmid">23986355</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Bilimoria</surname><given-names>KY</given-names></name><name><surname>Talamonti</surname><given-names>MS</given-names></name><name><surname>Tomlinson</surname><given-names>JS</given-names></name><name><surname>Stewart</surname><given-names>AK</given-names></name><name><surname>Winchester</surname><given-names>DP</given-names></name><name><surname>Ko</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients</article-title><source>Ann Surg</source><year>2008</year><volume>247</volume><issue>3</issue><fpage>490</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">18376195</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247(3):490&#x02013;500.<pub-id pub-id-type="pmid">18376195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Kutlu</surname><given-names>OC</given-names></name><name><surname>Dasari</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>JA</given-names></name><name><surname>Vauthey</surname><given-names>J-N</given-names></name><name><surname>Adams</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Prognostic value of Lymph Node Status and Extent of Lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas</article-title><source>J Gastrointest Surg</source><year>2016</year><volume>20</volume><issue>12</issue><fpage>1966</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">27714644</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Conrad C, Kutlu OC, Dasari A, Chan JA, Vauthey J-N, Adams DB, et al. Prognostic value of Lymph Node Status and Extent of Lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas. J Gastrointest Surg. 2016;20(12):1966&#x02013;74.<pub-id pub-id-type="pmid">27714644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Giulianotti</surname><given-names>PC</given-names></name><name><surname>Coratti</surname><given-names>A</given-names></name><name><surname>Angelini</surname><given-names>M</given-names></name><name><surname>Sbrana</surname><given-names>F</given-names></name><name><surname>Cecconi</surname><given-names>S</given-names></name><name><surname>Balestracci</surname><given-names>T</given-names></name><etal/></person-group><article-title>Robotics in general surgery: personal experience in a large community hospital</article-title><source>Arch Surg</source><year>2003</year><volume>138</volume><issue>7</issue><fpage>777</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">12860761</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Giulianotti PC, Coratti A, Angelini M, Sbrana F, Cecconi S, Balestracci T, et al. Robotics in general surgery: personal experience in a large community hospital. Arch Surg. 2003;138(7):777&#x02013;84.<pub-id pub-id-type="pmid">12860761</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>D</given-names></name><name><surname>Morris-Stiff</surname><given-names>G</given-names></name><name><surname>Falk</surname><given-names>GA</given-names></name><name><surname>El-Hayek</surname><given-names>K</given-names></name><name><surname>Chalikonda</surname><given-names>S</given-names></name><name><surname>Walsh</surname><given-names>RM</given-names></name></person-group><article-title>Robotic surgery of the pancreas</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><issue>40</issue><fpage>14726</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">25356035</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Joyce D, Morris-Stiff G, Falk GA, El-Hayek K, Chalikonda S, Walsh RM. Robotic surgery of the pancreas. World J Gastroenterol. 2014;20(40):14726&#x02013;32.<pub-id pub-id-type="pmid">25356035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Klotz</surname><given-names>R</given-names></name><name><surname>Mihaljevic</surname><given-names>AL</given-names></name><name><surname>Kulu</surname><given-names>Y</given-names></name><name><surname>Sander</surname><given-names>A</given-names></name><name><surname>Klose</surname><given-names>C</given-names></name><name><surname>Behnisch</surname><given-names>R</given-names></name><etal/></person-group><article-title>Robotic versus open partial pancreatoduodenectomy (EUROPA): a randomised controlled stage 2b trial</article-title><source>Lancet Reg Health Eur</source><year>2024</year><volume>39</volume><fpage>100864</fpage><pub-id pub-id-type="pmid">38420108</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Klotz R, Mihaljevic AL, Kulu Y, Sander A, Klose C, Behnisch R, et al. Robotic versus open partial pancreatoduodenectomy (EUROPA): a randomised controlled stage 2b trial. Lancet Reg Health Eur. 2024;39:100864.<pub-id pub-id-type="pmid">38420108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>de Rooij</surname><given-names>T</given-names></name><name><surname>van Hilst</surname><given-names>J</given-names></name><name><surname>van Santvoort</surname><given-names>H</given-names></name><name><surname>Boerma</surname><given-names>D</given-names></name><name><surname>van den Boezem</surname><given-names>P</given-names></name><name><surname>Daams</surname><given-names>F</given-names></name><etal/></person-group><article-title>Minimally invasive Versus Open Distal pancreatectomy (LEOPARD): a Multicenter patient-blinded Randomized Controlled Trial</article-title><source>Ann Surg</source><year>2019</year><volume>269</volume><issue>1</issue><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30080726</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">de Rooij T, van Hilst J, van Santvoort H, Boerma D, van den Boezem P, Daams F, et al. Minimally invasive Versus Open Distal pancreatectomy (LEOPARD): a Multicenter patient-blinded Randomized Controlled Trial. Ann Surg. 2019;269(1):2&#x02013;9.<pub-id pub-id-type="pmid">30080726</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Korrel</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>LR</given-names></name><name><surname>van Hilst</surname><given-names>J</given-names></name><name><surname>Balzano</surname><given-names>G</given-names></name><name><surname>Bj&#x000f6;rnsson</surname><given-names>B</given-names></name><name><surname>Boggi</surname><given-names>U</given-names></name><etal/></person-group><article-title>Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial</article-title><source>Lancet Reg Health Eur</source><year>2023</year><volume>31</volume><fpage>100673</fpage><pub-id pub-id-type="pmid">37457332</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Korrel M, Jones LR, van Hilst J, Balzano G, Bj&#x000f6;rnsson B, Boggi U, et al. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Lancet Reg Health Eur. 2023;31:100673.<pub-id pub-id-type="pmid">37457332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Dai</surname><given-names>M</given-names></name></person-group><article-title>Robotic versus laparoscopic distal pancreatectomy on perioperative outcomes: a systematic review and meta-analysis</article-title><source>Updates Surg</source><year>2023</year><volume>75</volume><issue>1</issue><fpage>7</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">36378464</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Li P, Zhang H, Chen L, Liu T, Dai M. Robotic versus laparoscopic distal pancreatectomy on perioperative outcomes: a systematic review and meta-analysis. Updates Surg. 2023;75(1):7&#x02013;21.<pub-id pub-id-type="pmid">36378464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Partelli</surname><given-names>S</given-names></name><name><surname>Andreasi</surname><given-names>V</given-names></name><name><surname>Rancoita</surname><given-names>PMV</given-names></name><name><surname>Perez-Sanchez</surname><given-names>E</given-names></name><name><surname>Muffatti</surname><given-names>F</given-names></name><name><surname>Balzano</surname><given-names>G</given-names></name><etal/></person-group><article-title>Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting</article-title><source>Surg Endosc</source><year>2021</year><volume>35</volume><issue>1</issue><fpage>165</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">31953734</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Partelli S, Andreasi V, Rancoita PMV, Perez-Sanchez E, Muffatti F, Balzano G, et al. Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting. Surg Endosc. 2021;35(1):165&#x02013;73.<pub-id pub-id-type="pmid">31953734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Zheng J, Pulvirenti A, Javed AA, Michelakos T, Paniccia A, Lee KK, et al. J Am Coll Surg. 2022;235(2):315&#x02013;30.</mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Pavone</surname><given-names>M</given-names></name><name><surname>Seeliger</surname><given-names>B</given-names></name><name><surname>Teodorico</surname><given-names>E</given-names></name><name><surname>Goglia</surname><given-names>M</given-names></name><name><surname>Taliento</surname><given-names>C</given-names></name><name><surname>Bizzarri</surname><given-names>N</given-names></name><etal/></person-group><article-title>Ultrasound-guided robotic surgical procedures: a systematic review</article-title><source>Surg Endosc</source><year>2024</year><volume>38</volume><issue>5</issue><fpage>2359</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">38512350</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Pavone M, Seeliger B, Teodorico E, Goglia M, Taliento C, Bizzarri N, et al. Ultrasound-guided robotic surgical procedures: a systematic review. Surg Endosc. 2024;38(5):2359&#x02013;70.<pub-id pub-id-type="pmid">38512350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Paiella</surname><given-names>S</given-names></name><name><surname>De Pastena</surname><given-names>M</given-names></name><name><surname>Landoni</surname><given-names>L</given-names></name><name><surname>Esposito</surname><given-names>A</given-names></name><name><surname>Casetti</surname><given-names>L</given-names></name><name><surname>Miotto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Is there a role for near-infrared technology in laparoscopic resection of pancreatic neuroendocrine tumors? Results of the COLPAN colour-and-resect the pancreas study</article-title><source>Surg Endosc</source><year>2017</year><volume>31</volume><issue>11</issue><fpage>4478</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">28374260</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Paiella S, De Pastena M, Landoni L, Esposito A, Casetti L, Miotto M, et al. Is there a role for near-infrared technology in laparoscopic resection of pancreatic neuroendocrine tumors? Results of the COLPAN colour-and-resect the pancreas study. Surg Endosc. 2017;31(11):4478&#x02013;84.<pub-id pub-id-type="pmid">28374260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>li</surname><given-names>W</given-names></name><name><surname>Nie&#x000df;en</surname><given-names>A</given-names></name><name><surname>Uzunoglu</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Minimally invasive versus open surgery for non-functioning pancreatic neuroendocrine tumors: a systematic review and meta-analysis</article-title><source>Int J Surg</source><year>2024</year><pub-id pub-id-type="doi">10.1097/JS9.0000000000002143</pub-id><pub-id pub-id-type="pmid">39806757</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Wei K, Zheng Q, Cheng L, li W, Nie&#x000df;en A, Uzunoglu FG, et al. Minimally invasive versus open surgery for non-functioning pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Int J Surg. 2024. 10.1097/JS9.0000000000002143.<pub-id pub-id-type="pmid">39806757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Bockhorn</surname><given-names>M</given-names></name><name><surname>Uzunoglu</surname><given-names>FG</given-names></name><name><surname>Adham</surname><given-names>M</given-names></name><name><surname>Imrie</surname><given-names>C</given-names></name><name><surname>Milicevic</surname><given-names>M</given-names></name><name><surname>Sandberg</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of pancreatic surgery (ISGPS)</article-title><source>Surgery</source><year>2014</year><volume>155</volume><issue>6</issue><fpage>977</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">24856119</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of pancreatic surgery (ISGPS). Surgery. 2014;155(6):977&#x02013;88.<pub-id pub-id-type="pmid">24856119</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Hackert</surname><given-names>T</given-names></name><name><surname>Klaiber</surname><given-names>U</given-names></name><name><surname>Pausch</surname><given-names>T</given-names></name><name><surname>Mihaljevic</surname><given-names>AL</given-names></name><name><surname>B&#x000fc;chler</surname><given-names>MW</given-names></name></person-group><article-title>Fifty years of surgery for pancreatic Cancer</article-title><source>Pancreas</source><year>2020</year><volume>49</volume><issue>8</issue><fpage>1005</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">32833940</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Hackert T, Klaiber U, Pausch T, Mihaljevic AL, B&#x000fc;chler MW. Fifty years of surgery for pancreatic Cancer. Pancreas. 2020;49(8):1005&#x02013;13.<pub-id pub-id-type="pmid">32833940</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Hackert</surname><given-names>T</given-names></name><name><surname>Klaiber</surname><given-names>U</given-names></name><name><surname>Hinz</surname><given-names>U</given-names></name><name><surname>Strunk</surname><given-names>S</given-names></name><name><surname>Loos</surname><given-names>M</given-names></name><name><surname>Strobel</surname><given-names>O</given-names></name><etal/></person-group><article-title>Portal vein resection in pancreatic Cancer surgery: risk of thrombosis and Radicality Determine Survival</article-title><source>Ann Surg</source><year>2023</year><volume>277</volume><issue>6</issue><fpage>e1291</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">35793384</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Hackert T, Klaiber U, Hinz U, Strunk S, Loos M, Strobel O, et al. Portal vein resection in pancreatic Cancer surgery: risk of thrombosis and Radicality Determine Survival. Ann Surg. 2023;277(6):e1291&#x02013;8.<pub-id pub-id-type="pmid">35793384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name></person-group><article-title>Pancreatectomy combined with superior mesenteric vein&#x02013;portal vein resection for pancreatic cancer: a meta-analysis</article-title><source>World J Surg</source><year>2012</year><volume>36</volume><issue>4</issue><fpage>1</fpage></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein&#x02013;portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36(4):1.</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Norton</surname><given-names>JA</given-names></name><name><surname>Harris</surname><given-names>EJ</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Visser</surname><given-names>BC</given-names></name><name><surname>Poultsides</surname><given-names>GA</given-names></name><name><surname>Kunz</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection</article-title><source>Arch Surg</source><year>2011</year><volume>146</volume><issue>6</issue><fpage>724</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">21690450</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146(6):724&#x02013;32.<pub-id pub-id-type="pmid">21690450</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Nie&#x000df;en</surname><given-names>A</given-names></name><name><surname>Klaiber</surname><given-names>U</given-names></name><name><surname>Lewosinska</surname><given-names>M</given-names></name><name><surname>Nickel</surname><given-names>F</given-names></name><name><surname>Billmann</surname><given-names>F</given-names></name><name><surname>Hinz</surname><given-names>U</given-names></name><etal/></person-group><article-title>Portal vein resection in pancreatic neuroendocrine neoplasms</article-title><source>Surgery</source><year>2024</year><volume>175</volume><issue>4</issue><fpage>1154</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">38262817</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Nie&#x000df;en A, Klaiber U, Lewosinska M, Nickel F, Billmann F, Hinz U, et al. Portal vein resection in pancreatic neuroendocrine neoplasms. Surgery. 2024;175(4):1154&#x02013;61.<pub-id pub-id-type="pmid">38262817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Gudmundsdottir</surname><given-names>H</given-names></name><name><surname>Tomlinson</surname><given-names>JL</given-names></name><name><surname>Graham</surname><given-names>RP</given-names></name><name><surname>Thiels</surname><given-names>CA</given-names></name><name><surname>Warner</surname><given-names>SG</given-names></name><name><surname>Smoot</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Outcomes of pancreatectomy with portomesenteric venous resection and reconstruction for locally advanced pancreatic neuroendocrine neoplasms</article-title><source>HPB (Oxford)</source><year>2022</year><volume>24</volume><issue>7</issue><fpage>1186</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">35078716</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Gudmundsdottir H, Tomlinson JL, Graham RP, Thiels CA, Warner SG, Smoot RL, et al. Outcomes of pancreatectomy with portomesenteric venous resection and reconstruction for locally advanced pancreatic neuroendocrine neoplasms. HPB (Oxford). 2022;24(7):1186&#x02013;93.<pub-id pub-id-type="pmid">35078716</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Fusai</surname><given-names>GK</given-names></name><name><surname>Tamburrino</surname><given-names>D</given-names></name><name><surname>Partelli</surname><given-names>S</given-names></name><name><surname>Lykoudis</surname><given-names>P</given-names></name><name><surname>Pipan</surname><given-names>P</given-names></name><name><surname>Di Salvo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study</article-title><source>Surgery</source><year>2021</year><volume>169</volume><issue>5</issue><fpage>1093</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">33357999</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Fusai GK, Tamburrino D, Partelli S, Lykoudis P, Pipan P, Di Salvo F, et al. Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study. Surgery. 2021;169(5):1093&#x02013;101.<pub-id pub-id-type="pmid">33357999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Bettini</surname><given-names>R</given-names></name><name><surname>Mantovani</surname><given-names>W</given-names></name><name><surname>Boninsegna</surname><given-names>L</given-names></name><name><surname>Crippa</surname><given-names>S</given-names></name><name><surname>Capelli</surname><given-names>P</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas</article-title><source>Dig Liver Disease</source><year>2009</year><volume>41</volume><issue>1</issue><fpage>49</fpage><lpage>55</lpage></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Disease. 2009;41(1):49&#x02013;55.</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Solorzano</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Pisters</surname><given-names>PWT</given-names></name><name><surname>Vauthey</surname><given-names>JN</given-names></name><name><surname>Ayers</surname><given-names>GD</given-names></name><name><surname>Jean</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients</article-title><source>Surgery</source><year>2001</year><volume>130</volume><issue>6</issue><fpage>1078</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">11742342</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Solorzano CC, Lee JE, Pisters PWT, Vauthey JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130(6):1078&#x02013;85.<pub-id pub-id-type="pmid">11742342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaslow</surname><given-names>SR</given-names></name><name><surname>Hani</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>SM</given-names></name><name><surname>Wolfgang</surname><given-names>CL</given-names></name><name><surname>Sacks</surname><given-names>GD</given-names></name><name><surname>Berman</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: an analysis of the national cancer database</article-title><source>J Surg Oncol</source><year>2023</year><volume>128</volume><issue>2</issue><fpage>262</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">37042430</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Kaslow SR, Hani L, Cohen SM, Wolfgang CL, Sacks GD, Berman RS, et al. Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: an analysis of the national cancer database. J Surg Oncol. 2023;128(2):262&#x02013;70.<pub-id pub-id-type="pmid">37042430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>HL</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name></person-group><article-title>Palliative resection of primary tumor in metastatic nonfunctioning pancreatic neuroendocrine tumors</article-title><source>J Surg Res</source><year>2019</year><volume>243</volume><fpage>578</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">31031022</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Ye H, Xu HL, Shen Q, Zheng Q, Chen P. Palliative resection of primary tumor in metastatic nonfunctioning pancreatic neuroendocrine tumors. J Surg Res. 2019;243:578&#x02013;87.<pub-id pub-id-type="pmid">31031022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>RT</given-names></name><name><surname>Bodei</surname><given-names>L</given-names></name><name><surname>Capdevila</surname><given-names>J</given-names></name><name><surname>Couvelard</surname><given-names>A</given-names></name><name><surname>Falconi</surname><given-names>M</given-names></name><name><surname>Glasberg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Unmet needs in functional and nonfunctional pancreatic neuroendocrine neoplasms</article-title><source>Neuroendocrinology</source><year>2019</year><volume>108</volume><issue>1</issue><fpage>26</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">30282083</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, et al. Unmet needs in functional and nonfunctional pancreatic neuroendocrine neoplasms. Neuroendocrinology. 2019;108(1):26&#x02013;36.<pub-id pub-id-type="pmid">30282083</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Partelli</surname><given-names>S</given-names></name><name><surname>Bertani</surname><given-names>E</given-names></name><name><surname>Bartolomei</surname><given-names>M</given-names></name><name><surname>Perali</surname><given-names>C</given-names></name><name><surname>Muffatti</surname><given-names>F</given-names></name><name><surname>Grana</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms</article-title><source>Surgery</source><year>2018</year><volume>163</volume><issue>4</issue><fpage>761</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">29284590</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Partelli S, Bertani E, Bartolomei M, Perali C, Muffatti F, Grana CM, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2018;163(4):761&#x02013;7.<pub-id pub-id-type="pmid">29284590</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Sowa-Staszczak</surname><given-names>A</given-names></name><name><surname>Pach</surname><given-names>D</given-names></name><name><surname>Chrzan</surname><given-names>R</given-names></name><name><surname>Trofimiuk</surname><given-names>M</given-names></name><name><surname>Stefa&#x00144;ska</surname><given-names>A</given-names></name><name><surname>Tomaszuk</surname><given-names>M</given-names></name><etal/></person-group><article-title>Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2011</year><volume>38</volume><issue>9</issue><fpage>1669</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">21559978</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefa&#x00144;ska A, Tomaszuk M, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38(9):1669&#x02013;74.<pub-id pub-id-type="pmid">21559978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>JC</given-names></name><name><surname>Schaeffer</surname><given-names>DF</given-names></name><name><surname>Kirsch</surname><given-names>R</given-names></name><name><surname>Pollett</surname><given-names>A</given-names></name><name><surname>Manzoni</surname><given-names>M</given-names></name><name><surname>Riddell</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Ileal carcinoid tumors-small size belies deadly intent: high rate of nodal metastasis in tumors&#x02009;&#x02264;&#x02009;1&#x000a0;cm in size</article-title><source>Hum Pathol</source><year>2016</year><volume>56</volume><fpage>123</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">27327193</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Walsh JC, Schaeffer DF, Kirsch R, Pollett A, Manzoni M, Riddell RH, et al. Ileal carcinoid tumors-small size belies deadly intent: high rate of nodal metastasis in tumors&#x02009;&#x02264;&#x02009;1&#x000a0;cm in size. Hum Pathol. 2016;56:123&#x02013;7.<pub-id pub-id-type="pmid">27327193</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquer</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>T</given-names></name><name><surname>Hervieu</surname><given-names>V</given-names></name><name><surname>Forestier</surname><given-names>J</given-names></name><name><surname>Scoazec</surname><given-names>JY</given-names></name><name><surname>Lombard-Bohas</surname><given-names>C</given-names></name><etal/></person-group><article-title>Surgical Management of Small Bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis</article-title><source>Ann Surg Oncol</source><year>2015</year><volume>22</volume><issue>Suppl 3</issue><fpage>S742</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26014153</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Pasquer A, Walter T, Hervieu V, Forestier J, Scoazec JY, Lombard-Bohas C, et al. Surgical Management of Small Bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis. Ann Surg Oncol. 2015;22(Suppl 3):S742&#x02013;9.<pub-id pub-id-type="pmid">26014153</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Warner</surname><given-names>RR</given-names></name><name><surname>Ward</surname><given-names>SC</given-names></name><name><surname>Harpaz</surname><given-names>N</given-names></name><name><surname>Roayaie</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors</article-title><source>Neuroendocrinology</source><year>2015</year><volume>101</volume><issue>1</issue><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">25572143</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Kim MK, Warner RR, Ward SC, Harpaz N, Roayaie S, Schwartz ME, et al. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology. 2015;101(1):58&#x02013;65.<pub-id pub-id-type="pmid">25572143</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Daskalakis</surname><given-names>K</given-names></name><name><surname>Karakatsanis</surname><given-names>A</given-names></name><name><surname>St&#x000e5;lberg</surname><given-names>P</given-names></name><name><surname>Norl&#x000e9;n</surname><given-names>O</given-names></name><name><surname>Hellman</surname><given-names>P</given-names></name></person-group><article-title>Clinical signs of fibrosis in small intestinal neuroendocrine tumours</article-title><source>Br J Surg</source><year>2017</year><volume>104</volume><issue>1</issue><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">27861745</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Daskalakis K, Karakatsanis A, St&#x000e5;lberg P, Norl&#x000e9;n O, Hellman P. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg. 2017;104(1):69&#x02013;75.<pub-id pub-id-type="pmid">27861745</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Laskaratos</surname><given-names>FM</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Wilkins</surname><given-names>D</given-names></name><name><surname>Tuck</surname><given-names>A</given-names></name><name><surname>Ramakrishnan</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours</article-title><source>Neuroendocrinology</source><year>2018</year><volume>107</volume><issue>3</issue><fpage>292</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">30153671</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Laskaratos FM, Walker M, Wilkins D, Tuck A, Ramakrishnan S, Phillips E, et al. Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours. Neuroendocrinology. 2018;107(3):292&#x02013;304.<pub-id pub-id-type="pmid">30153671</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Niederle</surname><given-names>B</given-names></name><name><surname>Pape</surname><given-names>UF</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name><name><surname>Gross</surname><given-names>D</given-names></name><name><surname>Kelestimur</surname><given-names>F</given-names></name><name><surname>Knigge</surname><given-names>U</given-names></name><etal/></person-group><article-title>ENETS consensus guidelines update for neuroendocrine neoplasms of the Jejunum and Ileum</article-title><source>Neuroendocrinology</source><year>2016</year><volume>103</volume><issue>2</issue><fpage>125</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">26758972</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016;103(2):125&#x02013;38.<pub-id pub-id-type="pmid">26758972</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Lardi&#x000e8;re-Deguelte</surname><given-names>S</given-names></name><name><surname>de Mestier</surname><given-names>L</given-names></name><name><surname>App&#x000e9;r&#x000e9;</surname><given-names>F</given-names></name><name><surname>Vullierme</surname><given-names>MP</given-names></name><name><surname>Zappa</surname><given-names>M</given-names></name><name><surname>Hoeffel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Toward a preoperative classification of lymph node metastases in patients with small intestinal neuroendocrine tumors in the era of intestinal-sparing surgery</article-title><source>Neuroendocrinology</source><year>2016</year><volume>103</volume><issue>5</issue><fpage>552</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26445315</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Lardi&#x000e8;re-Deguelte S, de Mestier L, App&#x000e9;r&#x000e9; F, Vullierme MP, Zappa M, Hoeffel C, et al. Toward a preoperative classification of lymph node metastases in patients with small intestinal neuroendocrine tumors in the era of intestinal-sparing surgery. Neuroendocrinology. 2016;103(5):552&#x02013;9.<pub-id pub-id-type="pmid">26445315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>CS</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Phan</surname><given-names>A</given-names></name><name><surname>Charnsangavej</surname><given-names>C</given-names></name><name><surname>Abdalla</surname><given-names>EK</given-names></name><name><surname>Aloia</surname><given-names>T</given-names></name><etal/></person-group><article-title>Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors</article-title><source>World J Surg</source><year>2013</year><volume>37</volume><issue>7</issue><fpage>1695</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">23657749</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Landry CS, Lin HY, Phan A, Charnsangavej C, Abdalla EK, Aloia T, et al. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013;37(7):1695&#x02013;700.<pub-id pub-id-type="pmid">23657749</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Exploration of the exact prognostic significance of lymphatic metastasis in Jejunoileal neuroendocrine tumors</article-title><source>Ann Surg Oncol</source><year>2018</year><volume>25</volume><issue>7</issue><fpage>2067</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">29748891</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Chen L, Song Y, Zhang Y, Chen M, Chen J. Exploration of the exact prognostic significance of lymphatic metastasis in Jejunoileal neuroendocrine tumors. Ann Surg Oncol. 2018;25(7):2067&#x02013;74.<pub-id pub-id-type="pmid">29748891</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Zaidi</surname><given-names>MY</given-names></name><name><surname>Lopez-Aguiar</surname><given-names>AG</given-names></name><name><surname>Dillhoff</surname><given-names>M</given-names></name><name><surname>Beal</surname><given-names>E</given-names></name><name><surname>Poultsides</surname><given-names>G</given-names></name><name><surname>Makris</surname><given-names>E</given-names></name><etal/></person-group><article-title>Prognostic role of lymph node positivity and number of lymph nodes needed for accurately staging small-bowel neuroendocrine tumors</article-title><source>JAMA Surg</source><year>2019</year><volume>154</volume><issue>2</issue><fpage>134</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">30383112</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Zaidi MY, Lopez-Aguiar AG, Dillhoff M, Beal E, Poultsides G, Makris E, et al. Prognostic role of lymph node positivity and number of lymph nodes needed for accurately staging small-bowel neuroendocrine tumors. JAMA Surg. 2019;154(2):134&#x02013;40.<pub-id pub-id-type="pmid">30383112</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquer</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>T</given-names></name><name><surname>Rousset</surname><given-names>P</given-names></name><name><surname>Hervieu</surname><given-names>V</given-names></name><name><surname>Forestier</surname><given-names>J</given-names></name><name><surname>Lombard-Bohas</surname><given-names>C</given-names></name><etal/></person-group><article-title>Lymphadenectomy during small bowel neuroendocrine tumor surgery: the Concept of skip metastases</article-title><source>Ann Surg Oncol</source><year>2016</year><volume>23</volume><issue>Suppl 5</issue><fpage>804</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27613554</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Pasquer A, Walter T, Rousset P, Hervieu V, Forestier J, Lombard-Bohas C, et al. Lymphadenectomy during small bowel neuroendocrine tumor surgery: the Concept of skip metastases. Ann Surg Oncol. 2016;23(Suppl 5):804&#x02013;8.<pub-id pub-id-type="pmid">27613554</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Bartsch DK, Windel S, Kanngie&#x000df;er V, Jesinghaus M, Holzer K, Rinke A, et al. Vessel-sparing lymphadenectomy should be performed in small intestine neuroendocrine neoplasms. Cancers (Basel). 2022;14(15).</mixed-citation></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Ohrvall</surname><given-names>U</given-names></name><name><surname>Eriksson</surname><given-names>B</given-names></name><name><surname>Juhlin</surname><given-names>C</given-names></name><name><surname>Karacagil</surname><given-names>S</given-names></name><name><surname>Rastad</surname><given-names>J</given-names></name><name><surname>Hellman</surname><given-names>P</given-names></name><etal/></person-group><article-title>Method for dissection of mesenteric metastases in mid-gut carcinoid tumors</article-title><source>World J Surg</source><year>2000</year><volume>24</volume><issue>11</issue><fpage>1402</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11038214</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Ohrvall U, Eriksson B, Juhlin C, Karacagil S, Rastad J, Hellman P, et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg. 2000;24(11):1402&#x02013;8.<pub-id pub-id-type="pmid">11038214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MX</given-names></name><name><surname>Lopez-Aguiar</surname><given-names>AG</given-names></name><name><surname>Poultsides</surname><given-names>G</given-names></name><name><surname>Rocha</surname><given-names>F</given-names></name><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Fields</surname><given-names>R</given-names></name><etal/></person-group><article-title>Surgical treatment of neuroendocrine tumors of the terminal ileum or cecum: ileocecectomy versus right hemicolectomy</article-title><source>J Gastrointest Surg</source><year>2022</year><volume>26</volume><issue>6</issue><fpage>1266</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">35149952</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Li MX, Lopez-Aguiar AG, Poultsides G, Rocha F, Weber S, Fields R, et al. Surgical treatment of neuroendocrine tumors of the terminal ileum or cecum: ileocecectomy versus right hemicolectomy. J Gastrointest Surg. 2022;26(6):1266&#x02013;74.<pub-id pub-id-type="pmid">35149952</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Evers</surname><given-names>M</given-names></name><name><surname>Rinke</surname><given-names>A</given-names></name><name><surname>R&#x000fc;tz</surname><given-names>J</given-names></name><name><surname>Ramaswamy</surname><given-names>A</given-names></name><name><surname>Maurer</surname><given-names>E</given-names></name><name><surname>Bartsch</surname><given-names>DK</given-names></name></person-group><article-title>Prognostic factors in curative resected locoregional small intestine neuroendocrine neoplasms</article-title><source>World J Surg</source><year>2021</year><volume>45</volume><issue>4</issue><fpage>1109</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">33416940</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Evers M, Rinke A, R&#x000fc;tz J, Ramaswamy A, Maurer E, Bartsch DK. Prognostic factors in curative resected locoregional small intestine neuroendocrine neoplasms. World J Surg. 2021;45(4):1109&#x02013;17.<pub-id pub-id-type="pmid">33416940</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Walshaw</surname><given-names>J</given-names></name><name><surname>Huo</surname><given-names>B</given-names></name><name><surname>McClean</surname><given-names>A</given-names></name><name><surname>Gajos</surname><given-names>S</given-names></name><name><surname>Kwan</surname><given-names>JY</given-names></name><name><surname>Tomlinson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Innovation in gastrointestinal surgery: the evolution of minimally invasive surgery-a narrative review</article-title><source>Front Surg</source><year>2023</year><volume>10</volume><fpage>1193486</fpage><pub-id pub-id-type="pmid">37288133</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Walshaw J, Huo B, McClean A, Gajos S, Kwan JY, Tomlinson J, et al. Innovation in gastrointestinal surgery: the evolution of minimally invasive surgery-a narrative review. Front Surg. 2023;10:1193486.<pub-id pub-id-type="pmid">37288133</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>W</given-names></name><name><surname>Perez Holguin</surname><given-names>RA</given-names></name><name><surname>Olecki</surname><given-names>EJ</given-names></name><name><surname>Stahl</surname><given-names>KA</given-names></name><name><surname>Dixon</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Predictors and outcomes of minimally invasive surgery for small bowel neuroendocrine tumors: minimally invasive surgery for SBNETs</article-title><source>J Gastrointest Surg</source><year>2022</year><volume>26</volume><issue>6</issue><fpage>1252</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">35132564</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Wong W, Perez Holguin RA, Olecki EJ, Stahl KA, Dixon M, Peng J, et al. Predictors and outcomes of minimally invasive surgery for small bowel neuroendocrine tumors: minimally invasive surgery for SBNETs. J Gastrointest Surg. 2022;26(6):1252&#x02013;65.<pub-id pub-id-type="pmid">35132564</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Eneholm</surname><given-names>J</given-names></name><name><surname>Beka</surname><given-names>E</given-names></name><name><surname>Kot&#x000e1;n</surname><given-names>R</given-names></name><name><surname>Gimm</surname><given-names>O</given-names></name></person-group><article-title>A retrospective study comparing minimally invasive versus open surgical resection of small intestinal neuroendocrine neoplasms at a tertiary referral center</article-title><source>Eur J Surg Oncol</source><year>2024</year><volume>50</volume><issue>2</issue><fpage>107936</fpage><pub-id pub-id-type="pmid">38176259</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Eneholm J, Beka E, Kot&#x000e1;n R, Gimm O. A retrospective study comparing minimally invasive versus open surgical resection of small intestinal neuroendocrine neoplasms at a tertiary referral center. Eur J Surg Oncol. 2024;50(2):107936.<pub-id pub-id-type="pmid">38176259</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Ka&#x000e7;maz</surname><given-names>E</given-names></name><name><surname>van Eeden</surname><given-names>S</given-names></name><name><surname>Koppes</surname><given-names>JCC</given-names></name><name><surname>Kl&#x000fc;mpen</surname><given-names>HJ</given-names></name><name><surname>Bemelman</surname><given-names>WA</given-names></name><name><surname>van Nieveen</surname><given-names>EJM</given-names></name><etal/></person-group><article-title>Value of laparoscopy for resection of small-bowel neuroendocrine neoplasms including central mesenteric lymphadenectomy</article-title><source>Dis Colon Rectum</source><year>2021</year><volume>64</volume><issue>10</issue><fpage>1240</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">33661232</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Ka&#x000e7;maz E, van Eeden S, Koppes JCC, Kl&#x000fc;mpen HJ, Bemelman WA, van Nieveen EJM, et al. Value of laparoscopy for resection of small-bowel neuroendocrine neoplasms including central mesenteric lymphadenectomy. Dis Colon Rectum. 2021;64(10):1240&#x02013;8.<pub-id pub-id-type="pmid">33661232</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Yogo</surname><given-names>A</given-names></name><name><surname>Paciorek</surname><given-names>A</given-names></name><name><surname>Kasai</surname><given-names>Y</given-names></name><name><surname>Moon</surname><given-names>F</given-names></name><name><surname>Hirose</surname><given-names>K</given-names></name><name><surname>Corvera</surname><given-names>CU</given-names></name><etal/></person-group><article-title>Long-term survival outcomes after minimally invasive surgery for Ileal neuroendocrine tumors</article-title><source>Ann Surg Oncol</source><year>2024</year><volume>31</volume><issue>9</issue><fpage>5507</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">38797790</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, et al. Long-term survival outcomes after minimally invasive surgery for Ileal neuroendocrine tumors. Ann Surg Oncol. 2024;31(9):5507&#x02013;14.<pub-id pub-id-type="pmid">38797790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Alander</surname><given-names>JT</given-names></name><name><surname>Kaartinen</surname><given-names>I</given-names></name><name><surname>Laakso</surname><given-names>A</given-names></name><name><surname>P&#x000e4;til&#x000e4;</surname><given-names>T</given-names></name><name><surname>Spillmann</surname><given-names>T</given-names></name><name><surname>Tuchin</surname><given-names>VV</given-names></name><etal/></person-group><article-title>A review of indocyanine green fluorescent imaging in surgery</article-title><source>Int J Biomed Imaging</source><year>2012</year><volume>2012</volume><issue>1</issue><fpage>940585</fpage><pub-id pub-id-type="pmid">22577366</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Alander JT, Kaartinen I, Laakso A, P&#x000e4;til&#x000e4; T, Spillmann T, Tuchin VV, et al. A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging. 2012;2012(1):940585.<pub-id pub-id-type="pmid">22577366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Ka&#x000e7;maz</surname><given-names>E</given-names></name><name><surname>Slooter</surname><given-names>MD</given-names></name><name><surname>van Nieveen</surname><given-names>EJM</given-names></name><name><surname>Tanis</surname><given-names>PJ</given-names></name><name><surname>Engelsman</surname><given-names>AF</given-names></name></person-group><article-title>Fluorescence angiography guided resection of small bowel neuroendocrine neoplasms with mesenteric lymph node metastases</article-title><source>Eur J Surg Oncol</source><year>2021</year><volume>47</volume><issue>7</issue><fpage>1611</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">33353827</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Ka&#x000e7;maz E, Slooter MD, van Nieveen EJM, Tanis PJ, Engelsman AF. Fluorescence angiography guided resection of small bowel neuroendocrine neoplasms with mesenteric lymph node metastases. Eur J Surg Oncol. 2021;47(7):1611&#x02013;5.<pub-id pub-id-type="pmid">33353827</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Sarioglu</surname><given-names>AG</given-names></name><name><surname>Akgun</surname><given-names>E</given-names></name><name><surname>Uysal</surname><given-names>M</given-names></name><name><surname>Osman</surname><given-names>M</given-names></name><name><surname>Berber</surname><given-names>E</given-names></name></person-group><article-title>The utility of fluorescence imaging in detecting primary and metastatic small bowel carcinoid tumors</article-title><source>Am J Surg</source><year>2024</year><volume>232</volume><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">37945469</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Sarioglu AG, Akgun E, Uysal M, Osman M, Berber E. The utility of fluorescence imaging in detecting primary and metastatic small bowel carcinoid tumors. Am J Surg. 2024;232:3&#x02013;7.<pub-id pub-id-type="pmid">37945469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Xiu</surname><given-names>D</given-names></name></person-group><article-title>Determination of surgical margins in laparoscopic parenchyma-sparing hepatectomy of neuroendocrine tumors liver metastases using indocyanine green fluorescence imaging</article-title><source>Surg Endosc</source><year>2022</year><volume>36</volume><issue>6</issue><fpage>4408</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">35006372</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Wang G, Luo Y, Qi W, Yuan C, Xiu D. Determination of surgical margins in laparoscopic parenchyma-sparing hepatectomy of neuroendocrine tumors liver metastases using indocyanine green fluorescence imaging. Surg Endosc. 2022;36(6):4408&#x02013;16.<pub-id pub-id-type="pmid">35006372</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Kose</surname><given-names>E</given-names></name><name><surname>Rudin</surname><given-names>AV</given-names></name><name><surname>Kahramangil</surname><given-names>B</given-names></name><name><surname>Moore</surname><given-names>E</given-names></name><name><surname>Aydin</surname><given-names>H</given-names></name><name><surname>Donmez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Autofluorescence imaging of parathyroid glands: an assessment of potential indications</article-title><source>Surgery</source><year>2020</year><volume>167</volume><issue>1</issue><fpage>173</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">31526579</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Kose E, Rudin AV, Kahramangil B, Moore E, Aydin H, Donmez M, et al. Autofluorescence imaging of parathyroid glands: an assessment of potential indications. Surgery. 2020;167(1):173&#x02013;9.<pub-id pub-id-type="pmid">31526579</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Bertani</surname><given-names>E</given-names></name><name><surname>Mattana</surname><given-names>F</given-names></name><name><surname>Collamati</surname><given-names>F</given-names></name><name><surname>Ferrari</surname><given-names>ME</given-names></name><name><surname>Bagnardi</surname><given-names>V</given-names></name><name><surname>Frassoni</surname><given-names>S</given-names></name><etal/></person-group><article-title>Radio-guided surgery with a New-Generation &#x003b2;-Probe for radiolabeled somatostatin Analog, in patients with small intestinal neuroendocrine tumors</article-title><source>Ann Surg Oncol</source><year>2024</year><volume>31</volume><issue>7</issue><fpage>4189</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">38652200</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Bertani E, Mattana F, Collamati F, Ferrari ME, Bagnardi V, Frassoni S, et al. Radio-guided surgery with a New-Generation &#x003b2;-Probe for radiolabeled somatostatin Analog, in patients with small intestinal neuroendocrine tumors. Ann Surg Oncol. 2024;31(7):4189&#x02013;96.<pub-id pub-id-type="pmid">38652200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>El Lakis</surname><given-names>M</given-names></name><name><surname>Gianakou</surname><given-names>A</given-names></name><name><surname>Nockel</surname><given-names>P</given-names></name><name><surname>Wiseman</surname><given-names>D</given-names></name><name><surname>Tirosh</surname><given-names>A</given-names></name><name><surname>Quezado</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Radioguided surgery with Gallium 68 Dotatate for patients with neuroendocrine tumors</article-title><source>JAMA Surg</source><year>2019</year><volume>154</volume><issue>1</issue><fpage>40</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">30267071</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">El Lakis M, Gianakou A, Nockel P, Wiseman D, Tirosh A, Quezado MA, et al. Radioguided surgery with Gallium 68 Dotatate for patients with neuroendocrine tumors. JAMA Surg. 2019;154(1):40&#x02013;5.<pub-id pub-id-type="pmid">30267071</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Pawa</surname><given-names>N</given-names></name><name><surname>Clift</surname><given-names>AK</given-names></name><name><surname>Osmani</surname><given-names>H</given-names></name><name><surname>Drymousis</surname><given-names>P</given-names></name><name><surname>Cichocki</surname><given-names>A</given-names></name><name><surname>Flora</surname><given-names>R</given-names></name><etal/></person-group><article-title>Surgical management of patients with neuroendocrine neoplasms of the appendix: appendectomy or more</article-title><source>Neuroendocrinology</source><year>2018</year><volume>106</volume><issue>3</issue><fpage>242</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">28641291</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Pawa N, Clift AK, Osmani H, Drymousis P, Cichocki A, Flora R, et al. Surgical management of patients with neuroendocrine neoplasms of the appendix: appendectomy or more. Neuroendocrinology. 2018;106(3):242&#x02013;51.<pub-id pub-id-type="pmid">28641291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Pape</surname><given-names>UF</given-names></name><name><surname>Niederle</surname><given-names>B</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name><name><surname>Gross</surname><given-names>D</given-names></name><name><surname>Kelestimur</surname><given-names>F</given-names></name><name><surname>Kianmanesh</surname><given-names>R</given-names></name><etal/></person-group><article-title>ENETS Consensus guidelines for Neuroendocrine neoplasms of the appendix (excluding Goblet Cell Carcinomas)</article-title><source>Neuroendocrinology</source><year>2016</year><volume>103</volume><issue>2</issue><fpage>144</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">26730583</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, et al. ENETS Consensus guidelines for Neuroendocrine neoplasms of the appendix (excluding Goblet Cell Carcinomas). Neuroendocrinology. 2016;103(2):144&#x02013;52.<pub-id pub-id-type="pmid">26730583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Brighi</surname><given-names>N</given-names></name><name><surname>La Rosa</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Grillo</surname><given-names>F</given-names></name><name><surname>Pusceddu</surname><given-names>S</given-names></name><name><surname>Rinzivillo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Morphological factors related to nodal metastases in neuroendocrine tumors of the appendix: a multicentric retrospective study</article-title><source>Ann Surg</source><year>2020</year><volume>271</volume><issue>3</issue><fpage>527</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">29995678</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, et al. Morphological factors related to nodal metastases in neuroendocrine tumors of the appendix: a multicentric retrospective study. Ann Surg. 2020;271(3):527&#x02013;33.<pub-id pub-id-type="pmid">29995678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Nussbaum</surname><given-names>DP</given-names></name><name><surname>Speicher</surname><given-names>PJ</given-names></name><name><surname>Gulack</surname><given-names>BC</given-names></name><name><surname>Keenan</surname><given-names>JE</given-names></name><name><surname>Ganapathi</surname><given-names>AM</given-names></name><name><surname>Englum</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Management of 1- to 2-cm carcinoid tumors of the appendix: using the National Cancer Data Base to address controversies in general surgery</article-title><source>J Am Coll Surg</source><year>2015</year><volume>220</volume><issue>5</issue><fpage>894</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">25840530</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Nussbaum DP, Speicher PJ, Gulack BC, Keenan JE, Ganapathi AM, Englum BR, et al. Management of 1- to 2-cm carcinoid tumors of the appendix: using the National Cancer Data Base to address controversies in general surgery. J Am Coll Surg. 2015;220(5):894&#x02013;903.<pub-id pub-id-type="pmid">25840530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Steffen</surname><given-names>T</given-names></name><name><surname>Ebinger</surname><given-names>SM</given-names></name><name><surname>Warschkow</surname><given-names>R</given-names></name><name><surname>L&#x000fc;thi</surname><given-names>C</given-names></name><name><surname>Schmied</surname><given-names>BM</given-names></name><name><surname>Clerici</surname><given-names>T</given-names></name></person-group><article-title>Long-term survival is not impaired after the complete resection of neuroendocrine tumors of the appendix</article-title><source>World J Surg</source><year>2015</year><volume>39</volume><issue>11</issue><fpage>2670</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">26223340</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Steffen T, Ebinger SM, Warschkow R, L&#x000fc;thi C, Schmied BM, Clerici T. Long-term survival is not impaired after the complete resection of neuroendocrine tumors of the appendix. World J Surg. 2015;39(11):2670&#x02013;6.<pub-id pub-id-type="pmid">26223340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Groth</surname><given-names>SS</given-names></name><name><surname>Virnig</surname><given-names>BA</given-names></name><name><surname>Al-Refaie</surname><given-names>WB</given-names></name><name><surname>Jarosek</surname><given-names>SL</given-names></name><name><surname>Jensen</surname><given-names>EH</given-names></name><name><surname>Tuttle</surname><given-names>TM</given-names></name></person-group><article-title>Appendiceal carcinoid tumors: predictors of lymph node metastasis and the impact of right hemicolectomy on survival</article-title><source>J Surg Oncol</source><year>2011</year><volume>103</volume><issue>1</issue><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">21031414</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Groth SS, Virnig BA, Al-Refaie WB, Jarosek SL, Jensen EH, Tuttle TM. Appendiceal carcinoid tumors: predictors of lymph node metastasis and the impact of right hemicolectomy on survival. J Surg Oncol. 2011;103(1):39&#x02013;45.<pub-id pub-id-type="pmid">21031414</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehrvarz Sarshekeh</surname><given-names>A</given-names></name><name><surname>Advani</surname><given-names>S</given-names></name><name><surname>Halperin</surname><given-names>DM</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>59</issue><fpage>99541</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">29245922</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Mehrvarz Sarshekeh A, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, et al. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget. 2017;8(59):99541&#x02013;51.<pub-id pub-id-type="pmid">29245922</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Rault-Petit</surname><given-names>B</given-names></name><name><surname>Do Cao</surname><given-names>C</given-names></name><name><surname>Guy&#x000e9;tant</surname><given-names>S</given-names></name><name><surname>Guimbaud</surname><given-names>R</given-names></name><name><surname>Rohmer</surname><given-names>V</given-names></name><name><surname>Juli&#x000e9;</surname><given-names>C</given-names></name><etal/></person-group><article-title>Current management and predictive factors of lymph node metastasis of appendix neuroendocrine tumors: a national study from the French group of endocrine tumors (GTE)</article-title><source>Ann Surg</source><year>2019</year><volume>270</volume><issue>1</issue><fpage>165</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">29557879</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Rault-Petit B, Do Cao C, Guy&#x000e9;tant S, Guimbaud R, Rohmer V, Juli&#x000e9; C, et al. Current management and predictive factors of lymph node metastasis of appendix neuroendocrine tumors: a national study from the French group of endocrine tumors (GTE). Ann Surg. 2019;270(1):165&#x02013;71.<pub-id pub-id-type="pmid">29557879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Nesti</surname><given-names>C</given-names></name><name><surname>Br&#x000e4;utigam</surname><given-names>K</given-names></name><name><surname>Benavent</surname><given-names>M</given-names></name><name><surname>Bernal</surname><given-names>L</given-names></name><name><surname>Boharoon</surname><given-names>H</given-names></name><name><surname>Botling</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1&#x02013;2&#x000a0;cm in size: a retrospective, Europe-wide, pooled cohort study</article-title><source>Lancet Oncol</source><year>2023</year><volume>24</volume><issue>2</issue><fpage>187</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">36640790</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Nesti C, Br&#x000e4;utigam K, Benavent M, Bernal L, Boharoon H, Botling J, et al. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1&#x02013;2&#x000a0;cm in size: a retrospective, Europe-wide, pooled cohort study. Lancet Oncol. 2023;24(2):187&#x02013;94.<pub-id pub-id-type="pmid">36640790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandraki</surname><given-names>KI</given-names></name><name><surname>Kaltsas</surname><given-names>G</given-names></name><name><surname>Grozinsky-Glasberg</surname><given-names>S</given-names></name><name><surname>Oleinikov</surname><given-names>K</given-names></name><name><surname>Kos-Kud&#x00142;a</surname><given-names>B</given-names></name><name><surname>Kogut</surname><given-names>A</given-names></name><etal/></person-group><article-title>The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN</article-title><source>Endocrine</source><year>2020</year><volume>70</volume><issue>1</issue><fpage>178</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">32524502</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Alexandraki KI, Kaltsas G, Grozinsky-Glasberg S, Oleinikov K, Kos-Kud&#x00142;a B, Kogut A, et al. The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN. Endocrine. 2020;70(1):178&#x02013;86.<pub-id pub-id-type="pmid">32524502</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>